Allergan’s Oral Drugs Overlooked In CGRP Inhibitor Development Race
Allergan has two oral CGRP inhibitors – the only small molecules in the drug class in the clinic – but anti-CGRP biologics are likely to hit the market first. However, an effective oral product from a company that’s already marketing a migraine drug – Botox – could be an overlooked contender.
You may also be interested in...
Teva Stands By Migraine Strategy After Ajovy Misses Boat On Express Scripts Deal
Agreement between Amgen/Novartis and Eli Lilly with Express Scripts on new migraine drugs could spur more demand by payers for simple, value-based outcomes deals.
Migraine Drug Atogepant Delivers Good News When Allergan Needs It Most
Oral CGRP inhibitor atogepant delivers strong Phase IIb/III results in episodic migraine prevention less than a week after activist investors went public with their push for a management shakeup to reverse Allergan's falling stock price.
Allergan's Ubrogepant Succeeds In Second Acute Migraine Phase III Study
The company intends to seek US FDA approval in the first half of 2019 for its CGRP inhibitor and believes that liver toxicity previously associated with oral drugs in this class are not a problem for its candidate ubrogepant.